Stemline Therapeutics’ (STML) “Buy” Rating Reiterated at Cowen and Company
Stemline Therapeutics, Inc. (NASDAQ:STML)‘s stock had its “buy” rating restated by stock analysts at Cowen and Company in a report released on Tuesday.
Several other equities research analysts have also weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $34.00 price objective on shares of Stemline Therapeutics in a research note on Tuesday, September 12th. ValuEngine lowered Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. BidaskClub upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, July 19th. Finally, Zacks Investment Research lowered Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. Stemline Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $32.60.
Shares of Stemline Therapeutics (NASDAQ:STML) traded up 29.86% on Tuesday, hitting $13.70. The stock had a trading volume of 2,578,675 shares. The firm’s 50-day moving average is $11.10 and its 200 day moving average is $9.29. The stock’s market cap is $321.33 million. Stemline Therapeutics has a 1-year low of $5.50 and a 1-year high of $14.60.
Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.18). The business had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.30 million. Stemline Therapeutics had a negative return on equity of 67.35% and a negative net margin of 4,176.84%. Equities analysts forecast that Stemline Therapeutics will post ($2.56) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Stemline Therapeutics’ (STML) “Buy” Rating Reiterated at Cowen and Company” was posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/31/stemline-therapeutics-stml-buy-rating-reiterated-at-cowen-and-company.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Voya Investment Management LLC bought a new stake in Stemline Therapeutics during the 2nd quarter worth approximately $102,000. Nationwide Fund Advisors lifted its holdings in Stemline Therapeutics by 7.8% during the 1st quarter. Nationwide Fund Advisors now owns 11,900 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 858 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Stemline Therapeutics by 3.8% during the 1st quarter. Wells Fargo & Company MN now owns 13,647 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 500 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in Stemline Therapeutics during the 2nd quarter worth $147,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in Stemline Therapeutics by 40.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 5,522 shares in the last quarter. Institutional investors and hedge funds own 48.34% of the company’s stock.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.